Abstract
Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer.
Highlights
Cancer is a chronic disease that leads to great mortality around the world and cancer cases are rising continuously [1]
The findings suggest that the administration of polymer-drug formulations intraductally can prolong ductal retention, resulting in reduced toxicity and enhanced sustained therapeutic outcomes [116]
The PAMAM-platinum conjugate displayed a survival rate at a minimum of 40.67% to a maximum of 67.45%, while the conjugate incorporated with both drugs displayed improved survival rate at a minimum of 55.47 to a maximum of 81.13% [118]. These findings revealed the potential of combining anticancer drugs with other therapeutic agents that are not anticancer agents using a polymer-based drug delivery system
Summary
Cancer is a chronic disease that leads to great mortality around the world and cancer cases are rising continuously [1]. Several research reports of polymer-drug conjugates designed for the treatment of breast cancer displayed unique features, such as high cytotoxic effects against the breast cancer cell lines [111,112], suitable for the combination of two anticancer drugs, resulting in synergistic effects [112,113,115,121,124,125], high selectivity towards cancer microenvironment, followed by tumor cell death and increased the survival rate in vivo [115], extended blood circulation [122], extended half-life [116], good stability [124,125], and improved water solubility of the incorporated drug [117]. The route of administration of the conjugates, such as intraductal administration, has prolonged the ductal retention of the conjugates [116]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.